0001140361-22-035329.txt : 20220930 0001140361-22-035329.hdr.sgml : 20220930 20220930084640 ACCESSION NUMBER: 0001140361-22-035329 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220930 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220930 DATE AS OF CHANGE: 20220930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eargo, Inc. CENTRAL INDEX KEY: 0001719395 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 273879804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39616 FILM NUMBER: 221282423 BUSINESS ADDRESS: STREET 1: 2665 NORTH FIRST STREET STREET 2: SUITE 300 CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 650-351-7700 MAIL ADDRESS: STREET 1: 2665 NORTH FIRST STREET STREET 2: SUITE 300 CITY: SAN JOSE STATE: CA ZIP: 95134 8-K 1 ny20004737x18_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2022


EARGO, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-39616
27-3879804
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

2665 North First Street, Suite 300
San Jose, California
95134
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (650) 351-7700

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered:
Common Stock, $0.0001 par value per share
   EAR
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


 
Item 8.01.          Other Events.

On September 30, 2022, Eargo, Inc. (the “Company”) issued a press release announcing that it will conduct a conference call on October 4, 2022 to discuss details of its recently commenced proxy solicitation campaign for the 2022 Annual Meeting of stockholders. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01.          Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.
  
Description
 
Press release dated September 30, 2022.
104
  
Cover Page Interactive Data File (embedded within the inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:
September 30, 2022
EARGO, INC.
       
   
By:
/s/ Adam Laponis
     
Adam Laponis
Chief Financial Officer


EX-99.1 2 ny20004737x18_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
Eargo to Hold Investor Update Conference Call on October 4, 2022

Company to Discuss Recently Commenced Proxy Solicitation Campaign for the 2022 Annual Meeting of Stockholders and the Importance of Voting as Soon as Possible


 •
Conference Call to be held on Tuesday, October 4, 2022 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

•
VOTE now to ensure the Company can conduct its proposed rights offering and repay or convert the convertible notes held by Patient Square Capital

SAN JOSE, Calif., Sept. 30, 2022 – (GLOBE NEWSWIRE) – Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced it will hold an Investor Update conference call and webcast on Tuesday, October 4, 2022, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss details of its recently commenced proxy solicitation campaign for the 2022 Annual Meeting of Stockholders, including important background and detailed information on why, and how, to vote for certain proposals that are critical to the Company and its stockholders.

Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 5336534. The live webinar of the call may also be accessed by visiting the Events and Presentations section of Eargo’s website at ir.eargo.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Eargo’s website for one year.

All proposals, including Proposal 4, which relates to the Company’s proposed reverse stock split, and Proposals 5 and 6, which relate to the Company’s proposed rights offering, will be voted upon at the Company’s 2022 Annual Meeting of Stockholders on October 12, 2022, as described in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on September 13, 2022. Eargo encourages ALL stockholders to vote, regardless of the number of shares held. Each of Proposals 4 and 5 requires a vote FOR by a majority of all outstanding shares. Shares that are not voted will have the same effect as votes AGAINST the proposal, and as such the Company urges ALL stockholders to participate and vote FOR each of Proposals 4 and 5. Your vote FOR Proposal 6 is also critical to enable us to complete our proposed rights offering


 •
Vote Online: To vote by proxy over the internet, visit www.proxyvote.com and follow the instructions provided on your proxy card or voting instruction form.

•
Vote by Telephone: You may vote with your proxy card by calling 1-800-690-6903 with a touch-tone phone to vote using an automated system. If you do not have your proxy card, you may call Morrow Sodali, our proxy solicitor, at 1-800-662-5200, Monday to Friday, 9:00 a.m. to 9:00 p.m. Eastern Time to speak with a proxy specialist.

•
Vote by Mail: To vote by mail, simply complete, sign and date you proxy card or voting instruction form and return it promptly in the envelope provided (by no later than October 5, 2022 in the case of a voting instruction form).

•
If you have any questions regarding our proposals or annual meeting, please call or email Morrow Sodali at 1-800-662-5200 or Ear.info@investor.morrowsodali.com.

•
For assistance with voting your shares, you can call Morrow Sodali at 1-877-787-9239.

•
Voting is a very simple process that should take no more than two minutes on your mobile device, laptop, desktop computer or tablet.

•
There are six matters scheduled for a vote at Eargo’s 2022 Annual Meeting. The Board of Directors recommends a vote “FOR” Proposals 1, 2, 4, 5 and 6 and a vote for “One Year” on Proposal 3. We need your vote “FOR” Proposals 5 and 6 to complete our proposed rights offering and FOR Proposal 4 to effect a reverse stock split. Vote FOR no matter how many or few shares you own.

•
Stockholders as of the close of business on September 6, 2022, the record date for the Annual Meeting, should vote their shares even if they no longer own them.

 
About Eargo

Eargo is a medical device company dedicated to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, completely-in-canal, FDA-regulated, Class I or Class II exempt devices indicated to compensate for mild to moderate hearing loss. Our differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, email or video chat. Eargo hearing aids are offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels in the United States.

Eargo’s sixth generation device, Eargo 6, is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. Eargo 6 is available for purchase here.

Related Links
http://eargo.com

Investor Contact
Nick Laudico
Senior Vice President of Corporate Strategy and Investor Relations
ir@eargo.com

#  #  #


Cautionary Statement Regarding Forward-Looking Statements

This communication and the scheduled conference call referenced herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  All statements other than statements of historical fact contained in this communication are forward-looking statements, including statements regarding the investment by Patient Square Capital, including the conversion of the notes, the terms of the anticipated rights offering, including the timing of the anticipated rights offering, or if it will occur at all, stockholder participation in the offering and the results of certain related proposals to be voted on by stockholders.  Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to the conversion of the notes issued pursuant to the Patient Square Capital investment; the timing of the anticipated rights offering, or if it will occur at all, stockholder participation in the offering and the results of certain related proposals to be voted on by stockholders.  These and other risks are described in greater detail under the section titled “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission (the “SEC”).  Any forward-looking statements in this communication are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, are based on current expectations, forecasts and assumptions, and speak only as of the date of this communication.  Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 
Additional Information and Where to Find It

The Company has filed a definitive proxy statement (as amended, the “Definitive Proxy Statement”) with the SEC for the Annual Meeting to which this communication relates and has mailed the Definitive Proxy Statement and other proxy solicitation materials to record holders as of September 6, 2022.  Before you vote, you should read the Definitive Proxy Statement and other documents the Company has filed with the SEC for more complete information about the Company, the 2022 Annual Meeting and the proposals to be voted on. The Company has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering.   You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain copies of the Definitive Proxy Statement and the other proxy solicitation materials, including a replacement proxy card, as well as the prospectus, by contacting Morrow Sodali, the Company’s proxy solicitor and the information agent for the offering, at:

Morrow Sodali LLC
333 Ludlow Street
5th Floor, South Tower
Stamford, Connecticut 06902
Individuals call toll-free: (800) 662-5200
Banks and Brokerage Firms, please call (203) 658-9400
E-mail: EAR.info@investor.morrowsodali.com

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of the Company’s common stock in respect of the proposals to be voted on by stockholders at the Company’s Annual Meeting. Information about the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is set forth in the Definitive Proxy Statement for the Annual Meeting, which was filed with the SEC on September 13, 2022, and in other documents filed by the Company, including on behalf of such individuals, with the SEC.

No Offer or Solicitation

This communication shall not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed rights offering or (ii) an offer, nor a solicitation of an offer, of the sale or purchase of securities, nor shall any securities of the Company be offered or sold in any jurisdiction in which such an offer, solicitation or sale would be unlawful. It is an outline of matters for discussion only.  Neither the SEC nor any state securities commission has approved or disapproved of the transactions contemplated hereby or determined if this document is truthful or complete. Any representation to the contrary is a criminal offense.  In connection with the proposed rights offering transaction discussed herein and the stockholder votes related thereto, a registration statement on Form S-1 (File No. 333-267071) (the “Registration Statement”) was filed with the SEC on August 25, 2022 and the Definitive Proxy Statement related to the Company’s 2022 Annual Meeting of Stockholders to be held on October 12, 2022 was filed with the SEC on September 13, 2022.  The Company intends to file other relevant materials with the SEC in connection with the proposals to be voted on by the stockholders.  Stockholders of the Company are urged to read the Registration Statement and the documents incorporated by reference therein and the Definitive Proxy Statement before making any voting or investment decision with respect to the stockholder proposals and the proposed rights offering, respectively, because they will contain important information regarding such proposals and the proposed rights offering transaction.  You should not construe the contents of this communication as legal, tax, accounting or investment advice or a recommendation.  You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein.

 EX-101.SCH 3 ear-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ear-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ear-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Sep. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 30, 2022
Entity File Number 001-39616
Entity Registrant Name EARGO, INC.
Entity Central Index Key 0001719395
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-3879804
Entity Address, Address Line One 2665 North First Street
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Jose
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95134
City Area Code 650
Local Phone Number 351-7700
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol EAR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 ny20004737x18_8k_htm.xml IDEA: XBRL DOCUMENT 0001719395 2022-09-30 2022-09-30 false 0001719395 8-K 2022-09-30 EARGO, INC. DE 001-39616 27-3879804 2665 North First Street Suite 300 San Jose CA 95134 650 351-7700 false false false false Common Stock, $0.0001 par value per share EAR NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( --%/E4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #313Y5,WM .\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$E*82;-9:6G#08K;.QF;+4UB_]@:R1]^R5>FS*V!]C1TL^? M/H%:%83R$9^C#QC)8+H;;>^24&'#3D1! "1U0BM3.27+3I*4)45L&Z> M&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33M4\/;T^)+7+8Q+ M))W"Z5&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #313Y5?FV0ZF$$ R$0 & 'AL+W=O5 2NX'G==V$"*+89.1/_]B[HV(#\ MBC\X.^BS8V(?92WEBQW,HI'C62(6L]!8"0I?>S9E<6R5@..?DZA3W-,&GA^_ MJS_F#P\/LZ::367\C4=F-W+Z#HG8AF:Q>9:'7]CI@7+ 4,8Z_R2'X[7MMD/" M3!N9G(*!(.'B^$U?3XDX#P@N! 2G@"#G/MXHI[RGAHZ'2AZ(LE>#FCW('S6/ M!C@N[*PLC8)?.<29\;T,,TBR(51$Y$$8;M[(3!QG&[(V= W;WY&(-H% M1!M5F0!!E%,\QG1;18'';VBL&<+1*3@ZUR5CP127MJ B F59F1=)6NFJJ!P#<_SFZU!U^\B/+V"IW<-SS/;?[TU""S^?0&H>H75/UKJ*8PAXK&X 01>R6?V5L5%Z[D0;)Z_J UZ"!8 M@P)K< W63(12I5+EUM0@2P.E1:0B4YD!+V#+J#*#N/C] T+H>Z61>M5/%0W3EQN207Y5:(^[)<-P<<=_2-;L5862NZY"*LG&]><3C"T MLD?XN+5_1%M(;7D;!!;H=M+;* M[N#CMOY%AI"3Q4X*K%W5B+0Z?K/7PZN][ P^;N@K;J!UR@WQ@Q_7/Y$E"S,% MV:K$PI6F,DG %I=&AB\-\KUW8WL%2:DB>QIGC*3PPJ=W5*$KH6P=/F[O*T4C M+K9D^9:L95R)6]-\)L_8>VS9( +PQT56W:QX]<(S2?+^\EO&%/9 M$H*K6L)#PM36)ND3*("7PPRE5%3.;8U@W9MDCWOU-\B58<*R))DX]5)= MB80+U2*5AA_4.+2,>'^"._#^RF=89D-4"XK(7 =VS';#]-^$KM?6L2-E.9]8/?9Q=\DXW\!4$L# M!!0 ( --%/E6?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5; M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/ M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_ M/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R! M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1< M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72 M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<' M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^ M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ] M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1 M/,<0F,7XC&894IT,/O'^8* \^>Q\E MTWLJ.?]74_P$4$L#!!0 ( --%/E67BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://eargo.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ny20004737x18_8k.htm ear-20220930.xsd ear-20220930_lab.xml ear-20220930_pre.xml ny20004737x18_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ny20004737x18_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ny20004737x18_8k.htm" ] }, "labelLink": { "local": [ "ear-20220930_lab.xml" ] }, "presentationLink": { "local": [ "ear-20220930_pre.xml" ] }, "schema": { "local": [ "ear-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ear", "nsuri": "http://eargo.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "ny20004737x18_8k.htm", "contextRef": "c20220930to20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://eargo.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "ny20004737x18_8k.htm", "contextRef": "c20220930to20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://eargo.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001140361-22-035329-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-035329-xbrl.zip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end